Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT06151938
Other study ID # NI-MT-08
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date November 21, 2023
Est. completion date August 20, 2025

Study information

Verified date March 2024
Source ALK-Abelló A/S
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The study is a single-center, observational design with a 12-month duration. Approximately 100 Chinese adult (18-65 years old) and adolescent (12-17 years old) with moderate to severe house dust mite (HDM) allergic rhinitis (AR) with or without allergic asthma (AA) who are newly prescribed ACARIZAX® will be recruited for evaluation of the relevance of measurement instruments. The instruments referred to three patient-report scales of allergic rhinitis symptom and quality-of-life including the Daily symptom score (DSS), Standardised rhinoconjunctivitis quality-of-life questionnaire [RQLQ(S)], and Visual analogue scale (VAS). Other data will be collected to evaluate the effectiveness and safety of ACARIZAX® under real-world clinical practices.


Description:

This is a prospective, non-interventional, observational, single-centre, open-label study. Chinese adult (18-65 years old) and adolescent (12-17 years old) HDM AR patients who are newly prescribed with ACARIZAX® at the discretion of attending physician, according to the approved indication by Hainan Provincial Health Commission, will be recruited for this study. Approximately 100 adult (18-65 years old) and adolescent (12-17 years old) patients are expected to be enrolled from Hainan Branch Hospital of Ruijin Hospital. Patients are included in the study only after the decision for treatment with ACARIZAX® has been made, and only with the objective of collecting relevant data about clinical effectiveness and safety of treatment with ACARIZAX® under real-world conditions. No further medical procedures beyond standard care at the discretion of the attending physician are necessary for participation in this study. Over the 13-month study (including 12-month of treatment), total of 5 scheduled visits will be documented: enrolment and first administration of ACARIZAX® (Visit 1, V0), and subsequent visits performed in 3-month intervals after the first administration at the third month (Visit 2, V1), sixth month (Visit 3, V2), ninth month (Visit 4, V3), and twelfth month (Visit 5, V4) respectively. The actual number and duration of follow-up visits are according to routine practice and may be changed at the physician's discretion. All adverse events (AE) will be collected from the first dose administration until 30 days after the last dose of ACARIZAX® (end of study).


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 100
Est. completion date August 20, 2025
Est. primary completion date May 20, 2025
Accepts healthy volunteers No
Gender All
Age group 12 Years to 65 Years
Eligibility Inclusion Criteria: - Adult and adolescent (12-65 years old) allergic rhinitis patients should meet each of the following criteria: - Adult with age of 18-65 years for allergic rhinitis with or without allergic asthma. Adolescent with age of 12-17 years for allergic rhinitis. - Clinical history and a positive test of dust mite sensitization (positive skin prick test result =+++ or positive specific IgE test result =grade 3). - Persistent moderate to severe dust mite allergic rhinitis despite use of symptom-relieving medication (symptom assessment defined as to assess symptoms of rhinitis by VAS score= 5). - Newly prescribed with ACARIZAX®. - For adults, must provide signed informed consent; for adolescents, written informed consent must be obtained from both guardian and patient himself/herself if the level of intellectual maturity makes it appropriate. - Patients with allergic asthma should also meet both of the following criteria: - Dust mite induced asthma not well controlled by inhaled corticosteroids and associated with mild to severe dust mite allergic rhinitis. - FEV1 = 70% of predicted value after adequate pharmacologic treatment. Exclusion Criteria: - Patients with hypersensitivity to any of the excipients. - Patients with severe asthma exacerbations within the last 3 months. - Asthmatic patients experiencing an acute respiratory tract infection should have the treatment postponed. - Patients with acute severe oral inflammation and oral wounds. - Patients who have previous treatment with Omalizumab within the last 120 days. - Patient who currently participates in or plan to participate in any interventional clinical study. - Any other reason that, in the investigator's opinion, makes the patient unsuitable to participate in this study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Standardised allergen extract from house dust mites
Drug: Allergen immunotherapy [ACARIZAX® (12-SQ HDM) house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet] for moderate to severe house dust mite allergic rhinitis with or without allergic asthma for 12 months.

Locations

Country Name City State
China Ruijin-Hainan Hospital Shanghai Jiao Tong University School of Medicine (Hainan Boao Research Hospital) Qionghai Hainan

Sponsors (1)

Lead Sponsor Collaborator
ALK-Abelló A/S

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in Asthma Control Questionnaire (ACQ) • Among patients with AR and AA, the change in Asthma Control Questionnaire (ACQ) from baseline to the 12th month of treatment (Visit 4).
[minimum: 0; maximum: 6; Higher score indicates worse asthma condition]
12 months
Other Change in the Forced Expiratory Volume in One Second (FEV1) • Among patients with AR and AA, the change in the Forced Expiratory Volume in One Second (FEV1) from baseline to the 12th month of treatment (Visit 4). 12 months
Other Change in the ratio of FEV1 and the Force Vital Capacity (FVC) • Among patients with AR and AA, the change in the ratio of FEV1 and the Force Vital Capacity (FVC), that is the FEV1/FVC, from baseline to the 12th month of treatment (Visit 4). 12 months
Other Change in the force mid-expiratory flow (FEF25-75%, FEF25%, FEF50%, FEF75%) value • Among patients with AR and AA, the change in the force mid-expiratory flow (FEF25-75%, FEF25%, FEF50%, FEF75%) value from baseline to the 12th month of treatment (Visit 4). 12 months
Other Change in the Fractional Exhaled Nitric Oxide (FeNO) • Among patients with AR and AA, the change in the Fractional Exhaled Nitric Oxide (FeNO) from baseline to the 12th month of treatment (Visit 4). 12 months
Other Total AR / (AR with AA) -related treatment costs To describe the total AR / (AR with AA) - related treatment costs 12 months in a 3-month interval.
Other AR / (AR with AA) -related treatment costs of each outpatient visit, emergency room visit, and hospitalization To describe the AR / (AR with AA) - related treatment costs and break down (if applicable) of each outpatient visit, emergency room visit, and hospitalization 12 months in a 3-month interval
Other Number of outpatient visit, emergency room visit, and hospitalization due to AR / (AR with AA) To describe the number of outpatient visit, emergency room visit, and hospitalization due to AR / (AR with AA) 12 months in a 3-month interval
Other Length of stay per hospitalization due to AR / (AR with AA) To describe the length of stay per hospitalization due to AR / (AR with AA) 12 months in a 3-month interval
Primary Correlation between three measurement instruments • The correlation between the score changes from baseline to 12 months of treatment (Visit 4) of three measurement instruments (as follows).
Measurement instruments include:
Daily symptom score (DSS) for 7 consecutive days [minimum: 0; maximum: 18; Higher score indicates worse symptoms ]
Standardised Rhinoconjunctivitis Quality of Life Questionnaire [RQLQ(S)] score, [minimum: 0; maximum: 168; Higher score indicates worse quality of life]
Visual Analog Scale (VAS) value of the global discomfort caused by AR. [minimum: 0mm; maximum: 100mm; Higher score indicates more discomfort caused by AR]
12 months
Secondary Change in average of Daily Medication Score (DMS) • The change in average of Daily Medication Score (DMS) for 7 consecutive days from baseline to 12th month of treatment (Visit 4).
[minimum: 0; maximum: 20; Higher score indicates more medication use]
12 months
Secondary Change in average of Total Combined Rhinitis Score (TCRS) • The change in average of Total Combined Rhinitis Score (TCRS) for 7 consecutive days from baseline to 12th month of treatment (Visit 4).
[TCRS= Rhinitis DSS+ Rhinitis DMS; minimum: 0; maximum: 24; Higher score indicates worse rhinitis symptoms and more rhinitis medication use]
12 months
Secondary To describe all adverse events (AE) and serious adverse events (SAE) • All AEs and SAEs from the study initiation to the end of study. up to 13 months
See also
  Status Clinical Trial Phase
Completed NCT03850626 - Validation of Combined Symptom Medication Score (cSMS) in Allergic Patients
Completed NCT02911688 - Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure Phase 2
Active, not recruiting NCT01776177 - The REALITY Study - a Real-life Long-term Analysis of Xolair Therapy N/A
Completed NCT00485576 - Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma Phase 2
Completed NCT00736801 - Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma N/A
Completed NCT00515775 - Influence of a Inhaled Corticosteroid Therapy Versus Corticosteroid + LABA Therapy on the FeNO of Asthmatic Children N/A
Completed NCT04259164 - Anti-inflammatory Effects Glycopyrronium Phase 3
Active, not recruiting NCT04619017 - Airway Immune Response to Allergens (Use Lay Language Here) Phase 1
Completed NCT01699594 - Change in Airway Responsiveness After Allergen Exposure N/A
Completed NCT00999466 - The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen Phase 2
Completed NCT01353755 - 2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma Phase 3
Completed NCT00434434 - A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma Phase 2
Completed NCT00492076 - Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma Phase 4
Completed NCT00490425 - Prevention of Asthma and Allergy by Probiotic Lactobacillus GG Phase 4
Completed NCT00829179 - Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma Phase 3
Recruiting NCT04542902 - Non-coding RNAs Analysis of Eosinophil Subtypes in Asthma N/A
Recruiting NCT04109534 - Effect of a Dietary Fatty Acid Supplementation on Symptoms and Bronchial Inflammation in Patients With Asthma N/A
Active, not recruiting NCT05186025 - Tyrosine Allergoid Paediatric and Adult Study
Withdrawn NCT03307278 - House Dust Mite Induced Inflammasome Activation on Corticosteroid Resistance N/A
Withdrawn NCT04401631 - Analytical Validation of the abioSCOPE Device With an IgE Test Panel: Point-of-Care Precision, Sample Type Comparison and Method Correlation